Zoetis Earnings Call Balances Strength And Strain
Zoetis ((ZTS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zoetis’ latest earnings call painted a mixed picture, as resilient livestock and international businesses helped offset sharp weakness in U.S. companion animal products. Management emphasized solid execution in diagnostics and margins, alongside a robust pipeline and targeted M&A, yet acknowledged near‑term pressures from competition, channel destocking and softer pet‑owner demand.
Solid Livestock Performance
Global livestock revenue rose to $720 million, up 12% year over year, with broad‑based gains across cattle, swine, poultry and fish. U.S. livestock sales advanced 7% to $225 million, supported by improved supply, spring promotional activity and rising vaccine adoption, and management framed this segment as a durable growth engine.
International Strength (Excluding Calendar Timing)
International revenue reached $1.1 billion, growing 17% on a reported basis and 10% organically, even after timing effects. Companion animal revenue outside the U.S. climbed 7%, while the Simparica franchise grew 14% overall and 29% for Trio, underscoring the long runway Zoetis sees in emerging markets.
Diagnostics and Reference Labs Momentum
Companion animal diagnostics revenue increased 10% to $113 million, driven by expansion of reference laboratories and strong uptake in chemistry and hematology platforms such as Vetscan Opticell. Management highlighted diagnostics as a resilient business tied to urgent and diagnostic care, less exposed to discretionary spending cuts.
Profitability and Margin Execution (Excluding FX)
Adjusted net income edged up to $646 million, reflecting 2% reported growth and 1% organic, while adjusted diluted EPS rose 7% helped by buybacks funded with convertible debt. Adjusted gross margin held at 71.8%, and excluding a roughly 150 basis‑point foreign‑exchange hit, underlying gross margin improved about 140 basis points on pricing and lower manufacturing costs.
Pipeline Strength and Strategic M&A
Zoetis touted a pipeline that includes 12 potential blockbuster products and more than $7 billion of incremental market opportunity across franchises. The announced acquisition of Neogen’s animal genomics business is intended to deepen its livestock genetics capabilities, reinforcing a strategy of focused business development to complement internal R&D.
Cost and Productivity Actions to Protect Profitability
The company launched a broad cost and productivity program aimed at tightening discretionary spending and boosting procurement and operating efficiencies. Management said these measures, which also include organizational adjustments, are designed to support a more leveraged profit and loss profile in 2026 and beyond and are reflected in updated earnings guidance.
Full-Year Guidance Maintained Positive Range
Zoetis maintained a positive tone on its full‑year outlook, calling for 2% to 5% organic operational revenue growth in 2026 on a base of $9.68 billion to $9.96 billion. Adjusted net income is projected to rise 2% to 6% to between $2.87 billion and $2.95 billion, signaling confidence that structural growth drivers can overcome current headwinds.
Flat Organic Revenue and Volume Decline in Q1
Global revenue for the quarter reached $2.3 billion, up 3% reported, but organic operational revenue was flat as volume declines offset pricing gains. The company said price contributed about 2% to growth while volume fell 2%, and excluding a roughly $100 million fiscal alignment timing shift, organic sales would have declined around 5%.
Significant U.S. and Companion Animal Weakness
U.S. revenue fell 8% to $1.1 billion, with U.S. companion animal sales down 11% to $865 million and global companion animal revenue sliding 4%. Management cited lower clinic traffic, greater price sensitivity among pet owners and softer demand for premium preventive and chronic care products as key drivers of the decline.
Dermatology Franchise Pressure
The dermatology franchise generated $347 million in revenue but declined 11% globally, with U.S. dermatology down 13% to $215 million. Flagship product Apoquel lost share to lower‑cost alternatives and aggressive competitive promotions, a dynamic worsened by falling patient volume in clinics.
OA Pain mAbs and Librela Declines
Monoclonal antibody therapies for osteoarthritis pain produced $140 million in combined revenue but fell 8% globally in the quarter. Librela revenue was $101 million, down 13% globally and 22% in the U.S., though management noted sequential stabilization, while Solensia delivered modest growth with a 6% increase globally and 2% in the U.S.
Parasiticides and Simparica Pressure
The Simparica parasiticide franchise brought in $385 million, down 1% overall, with Trio at $297 million off 1% and the core product at $88 million down 3%. U.S. Simparica revenue dropped 8% to $238 million as competitive entrants and aggressive promotions weighed on share, new patient starts and compliance.
Generic Competition Hit Non-Core Blockbusters
Generic rivals significantly eroded sales of previously high‑volume, non‑core blockbusters Convenia and Cerenia. Management acknowledged meaningful share loss in these brands, underscoring the broader pressure branded products face once generic alternatives reach the market.
Channel Destocking and Timing/Fiscal Alignment Effects
Shifts in distributor and retail purchasing patterns created additional drag, with slower replenishment and script denials curbing sales into the channel. Zoetis also noted that a fiscal‑year realignment moved about $100 million of revenue from a prior fourth quarter into the current first quarter, while foreign exchange shaved roughly 150 basis points off margins.
Slower Retail Growth and Ongoing Competitive Uncertainty
Retail revenue growth decelerated to the low double digits at roughly 10%, down from the 25% to 30% range seen previously. Management warned that ongoing competitive launches and macro‑driven price sensitivity are likely to persist, increasing uncertainty and driving a wider full‑year guidance range.
Forward-Looking Guidance and Outlook
For 2026, Zoetis expects organic operational revenue of $9.68 billion to $9.96 billion, up 2% to 5%, and adjusted net income of $2.87 billion to $2.95 billion, representing 2% to 6% growth. The company is targeting adjusted diluted EPS of $6.85 to $7.00 and an adjusted gross margin near 71.5%, assuming modest pricing, mid‑ to high‑single‑digit livestock growth and low‑ to mid‑single‑digit gains in key companion franchises.
Zoetis’ earnings call underscored a company balancing solid structural growth drivers against a challenging near‑term landscape in U.S. companion animal markets. Investors will be watching whether cost actions, pipeline execution and international expansion can offset competitive and macro pressures, and whether management’s cautiously optimistic guidance proves achievable.
